Industry reports
Editor highlights

Pharmasset Market and Forecasts, April 2014


 

» View Public Reports

1-10 of 18 reports for Pharmasset

Drug Discovery and Development in The United States and Georgia : Innovation and Technology Trends

  • Industry report
  • February 2013
  • 24 pages

... And acquisitions as well as portfolio planning, risk management and external scientific activities Participated in raising capital and building pharmasset from a company valued at $30 million in 2002 to $11 ...

U.S. Blood Supply, Tissue Banking and Transplantation Business

  • Industry report
  • September 2013
  • 30 pages
  • by Corporation

... Michael d. Rogers, ph.D. Chief development officer pharmasset chief development officer glaxosmithkline vice president, division of viral diseases, discovery medicine, hiv clinical research herv ...

The Indian Clinical Trial Market : Innovation and Technology Trends

  • Industry report
  • March 2012
  • 28 pages

... Astellas premier research shire prolexys duramed synta neurogesx auxilium az-seroquel novartis al pharma endoceutics pain therapeutic xanodyne az crestor poniard als (advance life science) pharmasset ...

Pharmaceutical Key Market Figures in The United States

  • Industry report
  • March 2012
  • 27 pages

... Johnson & johnson synthes 19,358 switzerland med tech takeda pharmaceutical nycomed 13,733 switzerland specialty pharma gilead pharmasset 11,012 usa specialty pharma teva cephalon 6,155 usa ...

Global Healthcare Sector Trends

  • Industry report
  • January 2012
  • 12 pages

... Of hepatitis c medicines, a market that may be worth $20bn by 2020. The acquisition follows gilead sciences' to buy experimental hepatitis c drug maker pharmasset for $10,8bn at a 94% premium ...

World Pharmaceutical Industry Analysis

  • Industry report
  • April 2012
  • 84 pages

... Miss/ ok comments pharmasset na 441% na h initially on robust data in hcv and partnering and later on acquisition regeneron $70 84% op h current price presents a good investment opportunity ...

U.S. Pharmaceutical Business Analysis

  • Industry report
  • July 2012
  • 172 pages
  • by Corporation

... pharmasset, now part of gilead 103 roche group development pipeline marketed products development programmes roche pharma global development programmes roche pharma research and early development genentech ...

Pharmaceutical Sector Analysis in The United States

  • Industry report
  • October 2012
  • 159 pages
  • by Corporation

... At week 12 after the end of the study treatment status Fpi q2 2012 recruitment expected to complete in q4 2012 rg7128 licensed from pharmasset, now part of gilead, setrobuvir Anadys pharmaceuticals inc ...

Pharmaceutical Industry Analysis in The United States and Japan

  • Industry report
  • August 2012
  • 187 pages
  • by Corporation

... Completed in q4 2012 Interim data publication target aasld 2013 mericitabine (rg7128) licensed from pharmasset, now part of gilead. Danoprevir=rg7227, setrobuvir=rg7790 patient population treatment ...

Pharmaceutical Sector Analysis in The United States and Japan

  • Industry report
  • August 2012
  • 187 pages
  • by Corporation

... And ifn-based quad regimens in patients who failed ifn/rbv 125mericitabine (rg7128) licensed from pharmasset, now part of gilead. Danoprevir=rg7227 126 roche group development pipeline marketed products ...

» Read our Company Profiles

1 Companies for Pharmasset

Roche Holding AG

Switzerland

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.